PA21

DRUG8 trials

Conditions

Chronic Kidney Disease Requiring Chronic DialysisChronic Kidney Disease Requiring HemodialysisDrug Interaction PotentiationHemodialysisHemodialysis Patients With HyperphosphatemiaHyperphosphatemiaPeritoneal Dialysis

Phase 1

A Drug-Drug Interaction Study of Warfarin and PA21

CompletedNCT01477424

Vifor PharmaDrug Interaction Potentiation

Start: 2011-11-30End: 2012-02-29Updated: 2012-02-16

A Drug-Drug Interaction Study of Digoxin and PA21

CompletedNCT01477411

Vifor PharmaDrug Interaction Potentiation

Start: 2011-11-30End: 2012-01-31Updated: 2012-01-18

Phase 2

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

CompletedNCT01521494

Kissei Pharmaceutical Co., Ltd.Chronic Kidney Disease Requiring Hemodialysis

Start: 2012-01-11End: 2012-07-03Updated: 2018-08-23

Phase 3

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

CompletedNCT01833494

Kissei Pharmaceutical Co., Ltd.Hemodialysis Patients With Hyperphosphatemia

Start: 2013-03-18End: 2014-08-04Updated: 2018-10-09

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

CompletedNCT01850641

Kissei Pharmaceutical Co., Ltd.Hemodialysis, Hyperphosphatemia

Start: 2013-04-29End: 2013-12-03Updated: 2018-10-09

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

CompletedNCT01850602

Kissei Pharmaceutical Co., Ltd.Hemodialysis, Hyperphosphatemia

Start: 2013-04-23End: 2013-12-10Updated: 2018-10-09

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

CompletedNCT01852682

Kissei Pharmaceutical Co., Ltd.Hyperphosphatemia, Peritoneal Dialysis

Updated: 2014-11-13

PA21 Safety and Efficacy in Adult Chinese Subjects

CompletedNCT03644264

Vifor Fresenius Medical Care Renal PharmaChronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia

Start: 2018-08-31End: 2020-08-21Updated: 2021-06-02

Related Papers

Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study